CJC-1295 vs Somatropin
Overview
CJC-1295 is primarily a performance & growth peptide, while Somatropin is used for hormonal.
This page compares CJC-1295 and Somatropin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Somatropin | |
|---|---|---|
| Category | Performance & Growth | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) |
| Frequency | weekly | daily subcutaneous injection |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | In labeled use, somatropin increases linear growth in children with growth failure from growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small size for gestational age and idiopathic short stature. In adults with diagnosed growth hormone deficiency, professional guidelines describe benefits in body composition, exercise capacity, skeletal integrity and quality-of-life measures, with the largest benefit in the most severely deficient patients. |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions. |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Somatropin falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Somatropin: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Somatropin is typically dosed at 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Somatropin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Somatropin?
- CJC-1295 is primarily a performance & growth peptide, while Somatropin is used for hormonal. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Somatropin is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Somatropin used for?
- Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults.
- Can you take CJC-1295 and Somatropin together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Somatropin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Somatropin FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Somatropin is FDA-approved for one or more indications.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- Somatropin — full monograph: mechanism, research, dosing & references